Leadership Team

"Affinity's Leadership Team is poised to deliver real results in real time."

Based in Cleveland, Ohio, Affinity was established in November 2010 by Drs. Julius Korley and Horst von Recum in collaboration with Case Western Reserve University. Recognizing the dynamic and rapidly changing medical and business environments we operate in, our staff is a vital part of Affinity’s accomplishments thus far. They are knowledgeable and extremely committed to Affinity’s continual ingenuity, reliability, and sustainability. Each staff member brings unique qualifications that are integral to Affinity’s continued success.



Dr. Julius Korley

Dr. Julius Korley is one of Affinity’s founders and the chief scientific officer of the company. Prior to co-founding Affinity, Dr. Korley gained valuable experience from being an early employee at Momenta Pharmaceuticals, a startup that matured into a publicly traded company. Because of his experience at Momenta—a once-small startup company that had an initial public offering after only three years — he knows of the insight, commitment and dedication required to see a project from start to maturation.

> Read more


Dr. Horst Von Recum

Co-founder of Affinity Therapeutics, Dr. Horst von Recum has more than 20 years of experience within the fields of chemical and biomedical engineering. A graduate of both Rice University (M.Ch.E) and the University of Utah (Ph.D.), Dr. von Recum spent his postdoctoral tenure conducting research at several of the country’s leading institutions, including MIT and Harvard Medical School.

Specializing in tissue engineering and affinity-based delivery of small molecule drugs and biomolecules, his expertise in these areas have led to innovative breakthroughs, resulting in numerous publications, patents, and achievements. Some noteworthy accomplishments include receiving the Ohio Cancer Research Associates Robert Trombly Award, the American Cancer Society’s Cuyahoga Pilot Award, and being nominated for the Controlled Release Society’s Young Investigator Award. Dr. von Recum also was granted the prestigious National Science Foundation CAREER award, a National Institutes of Health Challenge grant, as well as millions of dollars in funding from various sponsoring agencies throughout his career.

In addition to his current position with the company, he is also an associate professor at Case Western Reserve University and serves as director of the Center for Delivery of Molecules and Cells, which focuses on the creation of novel polymeric platforms for drug delivery and tissue engineering.

As co-founder of Affinity Therapeutics, Dr. von Recum plans to leverage his decades of research experience, ingenuity and insight, as well as available resources, to ensure company success and sustainability.

> view linkedin profile

> Read less



Dr. Sean Zuckerman

As senior research scientist for Affinity Therapeutics, Dr. Sean Zuckerman helps develop affinity-based drug delivery platforms into stand-alone products, generate in vivo data demonstrating product safety and efficacy, and write grants to obtain non-dilutive funding.

> Read more

Dr. Thomas Facklam

Dr. Thomas Facklam has been a business consultant with Affinity since the company’s inception. Dr. Facklam has more than 25 years of experience in all phases of product development, manufacturing, business development and strategic management in the pharmaceutical, biotech, diagnostic, medical device and agri-food industries. Using his broad technology development and commercialization and business experience, he has assisted companies and organizations to develop efficient business and product development strategies.

> Read more

    ©2013 Affinity Therapeutics, LLC. All Rights Reserved.   Site Development by Webster Marketing Solutions, Ltd. Site Design by jing.